3D illustration of the colon – Stock.adobe.com
The combination of fruquintinib (Fruzakura) and optimal supportive care led to
Results from an in-phase post-hoc analysis show that quality-adjusted time to absence of symptoms of disease or toxicity increased when compared with placebo and optimal supportive care in previously treated patients with metastatic colorectal cancer (CRC). The 3 FRESCO-2 study (NCT04322539) revealed a significant improvement in Q-TWiST. 2024 Gastrointestinal Cancer Symposium.1
Mean Q-TWiST was 6.25 months (95% CI, 5.89-6.61) in the fruquintinib group versus 4.21 months (95% CI, 3.81-4.60) in patients receiving placebo and best supportive care. (difference, 2.04, difference: 2.04). 95% CI, 1.51-2.57; P <.05). Furthermore, the mean time from randomization to toxic disease progression (TWiST) in each group was 4.06 months (95% CI, 3.75-4.36) vs. 1.92 months (95% CI, 1.75-2.10, difference 2.14; 95% CI). , 1.78-2.49. P <.05), mean time spent in grade 3/4 treatment-emergent adverse effects (TEAEs) from randomization to disease progression (TOX) was 0.45 months (95% CI, 0.37-0.53) versus 0.21 months (95% CI). , 0.15-0.28; difference, 0.24; 95% CI, 0.13-0.34; P <.05).
For patients in the fruquintinib group, the mean time from disease progression to death or censoring (REL) was 3.93 months (95% CI, 3.55 to 4.32) compared with 4.36 months (95% CI, 3.75 to 4.96). (difference, -0.43; 95% CI, -1.15 to 0.29; P ≧.05).
The researchers reported consistent improvement in Q-TWiST with fruquintinib combination in all patient subgroups except those with unknown primary tumor site and patients with right-sided and left-sided tumors. These outcomes are likely attributable to a very small number of patients within these subgroups. Based on sensitivity analysis, the mean duration of Q-TWIST was 6.41 months in the fruquintinib group and 4.26 months in the placebo group, with a difference in Q-TWIST of 2.14 months (95% CI, 1.61-2.68; P <.05), representing a relative 33.0% improvement with fruquintinib.
“Post-hoc Q-TWiST showed that fruquintinib slows disease progression and prolongs patient survival without significantly increasing toxicity. This is especially noteworthy considering the fact that it has been so successful,” said Sebastian Stinzing, MD, professor and dean of medicine. Professor of Hematology, Oncology and Tumor Immunology at the Charité University of Berlin said during his presentation: “Fruquintinib has the potential to improve quality of life and extend survival.” [QOL] For patients who have received previous treatment [metastatic] I am a patient with colorectal cancer who has limited treatment options. ”
In the FRESCO-2 trial, 691 patients with metastatic colorectal cancer from North America, Europe, Japan, and Australia received oral fruquintinib 5 mg (n = 461) or equivalent placebo (n = 230) and 2 patients in the best-of-breed treatment group. :1 randomly assigned. Supportive care is done as part of his 28-day cycle of 3 weeks on and 1 week off.
The primary endpoint of this trial was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, duration of response, safety, and health-related quality of life.
As part of the post-hoc Q-TWiST analysis, the researchers divided patients’ survival times into three health states: TOX, TWiST, and REL. The researchers calculated Q-TWiST as the utility-weighted sum of the average duration of each of the aforementioned health states. Additionally, we used Kaplan-Meier estimates to determine the average time spent in these health conditions in each treatment group.
The study also included a sensitivity analysis to account for serious AEs that may have affected patients’ quality of life and their ability to tolerate active treatment. For this analysis, Q-TWiST was recalculated using severe TEAEs rather than grade 3/4 TEAEs for TOX health status.
Results from the FRESCO-2 trial supported FDA approval of fruquintinib for metastatic colorectal cancer in November 2023.2 Specifically, this approval also extended to patients who had previously been treated with fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy and anti-VEGF agents. moreover, R.A.S. Wild-type disease previously treated with anticancer drugsEGFR Treatment was considered eligible for treatment with fruquintinib.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
I really appreciate this post. I have been looking everywhere for this! Thank goodness I found it on Bing. You have made my day! Thank you again
5559871531
certainly like your web-site but you need to check the spelling on quite a few of your posts. Many of them are rife with spelling issues and I in finding it very troublesome to inform the reality however I?¦ll definitely come again again.
Having fun with the patronage of Sir William Johnson, Superintendent of Indian Affairs, the firm began to trade with Illinois Nation ceded to Great Britain by France after the end of the French and Indian War, utilizing Fort Pitt Trading Publish in current-day Pittsburgh as a ahead base.
Australia beat Namibia 142-zero within the 2003 Rugby World Cup.
information.|My family members every time say that I am killing my time here
Hey, you used to write fantastic, but the last several posts have been kinda boring… I miss your great writings. Past several posts are just a little bit out of track! come on!
8US
First, make a paper template of the tabletop.
I need to to thank you for this excellent read!!I definitely loved every bit of it. I’ve got you bookmarked to look at new things you post…
Top88 cung cấp đa dạng các trò chơi hấp dẫn, từ game đánh bài, slot game cho đến các thử thách liên quan đến thể thao. Với tỷ lệ chiến thắng cao và phần thưởng hấp dẫn, Top88 mang đến cho người chơi trải nghiệm hấp dẫn, nơi họ có thể giành được chiến thắng và kiếm được những giải thưởng có giá trị.